European Specialty Pharma is the Focus for Novo Growth Equity - Again
This article was originally published in The Pink Sheet Daily
Executive Summary
Novo's $30 million investment in Orexo, following its $60 million financing of Archimedes, shows appeal of European specialty pharma.
You may also be interested in...
In Deals With Respivert And Orexo, J&J's Respiratory Push Gets Going
J&J acquired respiratory drug discovery firm Respivert and licensed two respiratory preclinical research programs from Orexo.
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”